All patients were treated according to the principle of pretreatment for nasopharyngeal carcinoma (NPC) patients at SYSUCC. Detailed pretreatment evaluation included complete history; physical examination, and fiber-optic endoscopic examination of the nasopharynx, oropharynx, and larynx; magnetic resonance imaging (MRI) or computerized tomography (CT) of the head and neck; a conventional work-up including chest radiography, abdominal sonography, and whole-body bone scanning using single-photon emission computed tomography (SPECT) or 18F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT).
concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13(2):163-71. ) Of patients receiving IMRT-plus-CCRT, a total of 315 patients (34.7%) were treated with platinum weekly, and 594 patients (65.3%) received 2 or 3 cycles of chemotherapy every 3 weeks.
All patients were treated with intensity-modulated radiotherapy (IMRT). The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements (ICRU) Reports No. 50 and No. 62. Specifically, the primary nasopharyngeal gross tumor volume (GTVnx) and corresponding cervical lymph nodes were determined based on MRI or CT imaging as well as clinical and endoscopic data. The enlarged retropharyngeal nodes together with primary gross tumor volume (GTV) were outlined as the GTVnx on the IMRT plans. The first clinical tumor volume (CTV1) was defined as the GTV within 0.5-1.0 cm margin (0.2 to 0.3 cm posterior margin) to encompass the high-risk sites of microscopic extension and the whole nasopharynx. Clinical target volume 2 (CTV2) was defined as the CTV1 plus a 0.5-1.0 cm margin (0.2 to 0.3 cm posterior margin) to encompass the low-risk sites of microscopic extension, the level of the lymph node, and the elective neck area (bilateral levels IIa, IIb, III, and Va are routinely covered for all N0 patients, whereas ipsilateral levels IV, Vb, and supraclavicular fossae were also included for the N1-3 patients). The prescribed doses were 66-70 Gy to the planning target volume (PTV), 60 Gy to PTV1, 54 Gy to PTV2, and 60-66 Gy to the PTV of the involved cervical lymph nodes in 28 to 33 fractions. All patients were treated once daily with five fractions weekly. And the intensity modulated radiotherapy quality assurance (QA) was performed before radiation treatment for all the NPC patients. Details of the radiation therapy techniques used at the SYSUCC were described in a previous study. 
Follow-up information
After completion of the treatment, the patients were subsequently examined every three months for the first three years and then every six months thereafter until death. At each follow-up visit, detailed history was collected, and a complete physical examination was performed. Specifically, nasopharyngoscopy, magnetic resonance imaging (MRI) scanning of the head and neck, chest radiography, abdominal sonography, and whole-body bone scanning using single-photon emission computed tomography (SPECT) or 18 F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT) were performed annually or when patients had clinical symptoms indicating tumour relapse.
Supplementary Figures Legends
Suppleme ntary Figure 1 Kaplan-Meier survival curves for overall survival, disease-free survival, metastasis-free survival, and locoregional relapse-free survival for four groups by magnitude (A, B, C, and D, respectively) and two groups according to a cutoff of 4000 copies per millilitre (E, F, G, and H, respectively). DFS, disease-free survival; DMFS, distant metastasis-free survival; EBV, Epstein-Barr virus; LRFS, locoregional relapse-free survival; OS, overall survival. for distant metastasis-free survival, but not for overall, disease-free, or locoregional relapse-free survivals, and detailed interaction information was presented in figure 3 .
Supplementary
b Due to small numbers of cases in these subgroups, the confident intervals were extremely wide but non-significant (N.S.). CI, confidence interval; EBV, Epstein-Barr virus; HR, hazard ratio; IPTW, inverse probability of treatment weighting; PSM, propensity score matching.
